Urothelial Cancer Overview

Save information for later
Sign Up

Learn About Urothelial Cancer

What is the definition of Urothelial Cancer?
Urothelial cancer, also known as transitional cell carcinoma, affects the kidney (renal) pelvis or ureter (tube) that drains urine from the kidney to the bladder and/or the lining of the inside of the bladder. It is the most common form of bladder cancer and occurs more frequently in men and older adults. The cause of urothelial cancer is unknown; however, some suspected causes are chronic irritation of the kidney from pain medicines, exposure to manufacturing chemicals and dyes, smoking or other tobacco use, past radiation exposure, and parasitic infections.
What are the symptoms of Urothelial Cancer?
Symptoms of urothelial cancer include fatigue, unexplained weight loss, loss of appetite, anemia, constant back pain, flank pain, pelvic pain, urinary urgency, pain, burning, or discomfort when urinating, or blood in urine (hematuria).
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Urothelial Cancer?
Treatment for urothelial cancer includes surgery and chemotherapy. Bladder cancer can recur after treatment; therefore, long-term follow-up is necessary.
Who are the top Urothelial Cancer Local Doctors?
Elite in Urothelial Cancer
Dr. Andrew J. Stephenson
Urology
Elite in Urothelial Cancer
Dr. Andrew J. Stephenson
Urology

Lutheran Medical Group LLC

7910 W Jefferson Blvd, Suite 112, 
Fort Wayne, IN 
 (59.2 mi)
260-969-7121
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Stephenson is an Urologist in Fort Wayne, Indiana. Dr. Stephenson and is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Bladder Cancer, Prostate Cancer, Urothelial Cancer, Prostatectomy, and Cystectomy. Dr. Stephenson is currently accepting new patients.

Elite in Urothelial Cancer
Dr. Amir Mortazavi
Oncology | Hematology Oncology
Elite in Urothelial Cancer
Dr. Amir Mortazavi
Oncology | Hematology Oncology

Osu Internal Medicine LLC

3900 Stoneridge Ln, 
Dublin, OH 
 (76.2 mi)
614-889-5001
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients

Amir Mortazavi is an Oncologist and a Hematologist Oncology provider in Dublin, Ohio. Dr. Mortazavi and is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, and Nephrectomy. Dr. Mortazavi is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Urothelial Cancer
Dr. Timothy G. Schuster
Urology
Distinguished in Urothelial Cancer
Dr. Timothy G. Schuster
Urology

Promedica Genito-Urinary Surgeons LLC

2120 W Central Ave, 
Toledo, OH 
 (99.3 mi)
419-531-8558
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Timothy Schuster is an Urologist in Toledo, Ohio. Dr. Schuster and is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Perirenal Abscess, Boils, Non-Muscle Invasive Bladder Cancer, Ureteroscopy, and Nephrectomy. Dr. Schuster is currently accepting new patients.

View All Doctors
What are the latest Urothelial Cancer Clinical Trials?
Enfortumab Vedotin in Combination with Pembrolizumab for Locally Advanced And/or Node Positive Urothelial Carcinoma Prior to Surgery (EV-ECLIPSE)
Enfortumab Vedotin in Combination with Pembrolizumab for Locally Advanced And/or Node Positive Urothelial Carcinoma Prior to Surgery (EV-ECLIPSE)
Who is this study for: Patients with locally advanced and/or node positive urothelial carcinoma prior to surgery
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Drug
Study Drugs: Enfortumab vedotin, Pembrolizumab
Study Phase: Phase 2

Summary: This study will test whether enfortumab vedotin combined with pembrolizumab is an effective treatment for people with bladder cancer (urothelial carcinoma) involving the lymph nodes who are going to have surgery to remove their cancer (cystectomy). The researchers will look at whether treatment with enfortumab vedotin and pembrolizumab before surgery can get rid of cancer within the lymph nodes. T...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Who is this study for: Adult patients with Genitourinary Tumors
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2

Summary: This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ...

View All Clinical Trials